The Indegene IPO is scheduled to hit the market on May 6 and will conclude on May 8, aiming to raise approximately ₹1848.94 crores. This includes a fresh issue of ₹760 crores and an offer for sale of up to 2,39,32,732 equity shares priced at ₹455 each. The IPO comprises a retail quota of 35%, QIB quota of 50%, and HNI quota of 15%.
Indegene specializes in providing digital-led commercialization services for the life sciences industry, serving biopharmaceutical, emerging biotech, and medical devices companies.
Their services span various aspects such as drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales and marketing of products. With over two decades of expertise in the healthcare domain and technology, Indegene enables life sciences companies to develop, launch, and market products effectively and efficiently.
As of December 31, 2023, Indegene had established relationships with the 20 largest biopharmaceutical companies globally, earning a significant portion of its revenue from these clients. The company had a total of 65 active clients, including those from whom it earned substantial revenues.
The IPO proceeds will be utilized for various purposes, including repayment/prepayment of indebtedness of one of its Material Subsidiaries, funding capital expenditure requirements, and general corporate purposes.
Financially, Indegene has demonstrated growth in revenue and profit over the years. For instance, in the financial year ending March 2023, the company reported revenue of ₹2364.10 crores and a profit after tax of ₹266.10 crores.
As of FY2023, Indegene’s valuation metrics include an EPS of ₹12.03 and a RoNW of 25.02%. Notably, Indegene is a professionally managed company without an identifiable promoter.
Investors can apply for the Indegene IPO through ASBA available in their bank accounts or by downloading IPO forms from NSE and BSE. The IPO allotment is expected to be finalized on May 9, with listing anticipated on May 13, 2024.
